Navigation Links
Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
Date:4/20/2009

P covering synthetic siRNAs and validating partnerships with companies such as Pfizer."

Dr. Thompson has been a leader in siRNA development for several years. Prior to joining Quark, he was Director of Research and Development at Genta, and previously was Director of Biology Research at Ribozyme Pharmaceuticals, which was acquired by Merck after changing its name to Sirna Therapeutics.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
4. Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer
5. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
6. Sunesis Pharmaceuticals Receives NASDAQ Notification
7. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
10. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
11. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... -- U.S. biotech company Kultevat has strengthened its ... developed by the Donald Danforth Plant Science Center ... applications in production of natural rubber in Taraxicum ... under the direction of Roger Beachy , Ph.D., ... the Danforth Plant Science Center, and is used to ...
(Date:9/18/2014)... LEXINGTON, Ky. , Sept. 18, 2014  Neogen ... it has entered into a strategic agreement with Merck ... Heifer Program. The Igenity Dairy Heifer ... producers essential information on the genetic potential of replacement ... after a calf is born, and is an excellent ...
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... Claire, Wis. - Anticipating a net loss in 2007, ... announced 165 layoffs at its Eau Claire manufacturing plant, according ... ,Job losses at the Eau Claire plant are part of ... plants in Hutchinson and Plymouth, Minn., and Sioux Falls, S.D. ...
... - The June 30 deadline is approaching ... to $223.9 million in benefits from a class ... to attorneys lawyers involved in the court-approved settlement. ... violated Wisconsin's antitrust and unfair competition laws. , ...
... Abandoned and failed information technology programs have cost state government ... that has some members of the Legislature wondering if it's ... the whole mess. , ,There's probably no need to hit ... cut-and-paste IT operations. Instead, lawmakers should look for best practices ...
Cached Biology Technology:June 30 is deadline to claim up to $223.9M in Microsoft settlement 2Ethics Board site offers welcome contrast to state IT mistakes 2Ethics Board site offers welcome contrast to state IT mistakes 3
(Date:9/21/2014)... of California, San Diego, have developed a program that ... activity of genes based on sequences of DNA. They ... to human embryonic cells in a paper published in ... of our cells have the same blueprint, the same ... lead author of the report. "Skin cells protect, nerve ...
(Date:9/21/2014)... was previously thought, newborn immune T cells may have ... according to a new study led by King,s College ... that of adults, babies may still be able to ... in the journal Nature Medicine . , Our ... of immune cells, including neutrophils which play an important ...
(Date:9/21/2014)... has developed a protein therapy that disrupts the process ... tumor sites, travel through the blood stream and start ... process, known as metastasis, can cause cancer to spread ... who succumb to cancer fall prey to metastatic forms ... of bioengineering who describes a new therapeutic approach in ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2Immune system of newborn babies is stronger than previously thought 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... (March 7, 2011) -- All our daily activities, from driving ... carried along the body,s vast network of neurons. Propagation of ... within nerve cells -- receptors, ion channels, and transmitters -- ... study of these molecules in real time has not been ...
... up pollution, protecting soil from erosion and maintaining species-rich ecosystems ... by a University of Houston (UH) scientist and his team. ... on a new method to speed up research in the ... computer science and mathematics at UH, and his fellow researchers ...
... Scientists have identified a single mutated gene that causes ... bone loss and osteoporosis (fragile bones). The study, published ... into possible causes of osteoporosis and highlights the gene ... , There are only 50 reported cases of ...
Cached Biology News:Protecting ecosystems, pollution remediation goals of research at UH 2Protecting ecosystems, pollution remediation goals of research at UH 3Gene responsible for severe osteoporosis disorder discovered 2
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Request Info...
Request Info...
Biology Products: